Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers. The medicine, a monoclonal antibody, would stimulate the immune system to attack the protein–killing the tumors.

Alzheimer's Association. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004

Reference

Title
Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research
Publisher
The Lewin Group
Publication Date
2004
Authors
Alzheimer's Association

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Widespread use of selective estrogen receptor modulators could result in an approximately 30% decrease in breast cancer.  
  • Cancer mortality declined more than 2% in 2003, a continuation of the decline that began in 1990.  
  • Incidence rates for colorectal cancer have been decreasing since 1985, from 66 to 52 per 100,000 in 2002.  
  • Medicines Prevent Cancer Recurrence: New breast cancer drug greatly reduces recurrence and death (5 to 10 years after diagnosis in postmenopausal women)  
  • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.